Based on the overexpressed ITLN1 in skin lesions of AD patients, further investigation confirmed that ITLN1 inhibitor could interfere with the phosphorylation of epidermal growth factor receptor (EGFR) and ERK and suppress the TH2 immune responses in vitro (Yi et al., 2017). The gene discussed is ITLN1; the disease is Alzheimer disease.